Johnson & Johnson (JNJ): Today's Featured Drugs Laggard

Johnson & Johnson (JNJ) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.8%. By the end of trading, Johnson & Johnson fell 90 cents (-1.3%) to $68.63 on average volume. Throughout the day, 13.8 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 15.6 million shares. The stock ranged in price between $68.35-$69.36 after having opened the day at $69.35 as compared to the previous trading day's close of $69.53. Other company's within the Drugs industry that declined today were: Somaxon Pharmaceuticals (SOMX), down 13%, pSivida (PSDV), down 12%, Novavax (NVAX), down 10.8%, and Supernus Pharmaceuticals (SUPN), down 10.8%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $190.52 billion and is part of the health care sector. The company has a P/E ratio of 22, above the average drugs industry P/E ratio of 19 and above the S&P 500 P/E ratio of 17.7. Shares are up 6% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

• You can view the full Johnson & Johnson Ratings Report.

On the positive front, Aoxing Pharmaceutical Company (AXN), up 24%, Astex Pharmaceuticals (ASTX), up 13.5%, Durect Corporation (DRRX), up 12.6%, and Onyx Pharmaceuticals (ONXX), up 11.7%, were all gainers within the drugs industry with Questcor Pharmaceuticals (QCOR) being today's featured drugs industry leader.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Johnson & Johnson click any of the following:

• Johnson & Johnson Stock Price

• Johnson & Johnson Analyst Ratings

• Johnson & Johnson Key Stats & Profile

• Johnson & Johnson Earnings

• Johnson & Johnson Ratio Comparison

• Johnson & Johnson Growth Rates

• Johnson & Johnson Balance Sheet

• Johnson & Johnson Cash Flow

• Johnson & Johnson Income Statement